NCT03471481

Brief Summary

The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Aug 2015

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 10, 2015

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

March 14, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 20, 2018

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2019

Completed
Last Updated

March 1, 2021

Status Verified

November 1, 2019

Enrollment Period

4 years

First QC Date

March 14, 2018

Last Update Submit

February 25, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Bone mineral density

    Will be measured at Tibia, Hip and Total Body using a DXA scan

    1 time point - baseline

Secondary Outcomes (2)

  • Ionized Magnesium in serum

    1 time point - baseline

  • Vitamin D - 25 hydroxy vitamin D

    1 time point - baseline

Interventions

No Intervention. Study is cross sectional in nature

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals diagnosed with epilepsy and on medications

You may qualify if:

  • Individuals receiving anti-epileptic drugs as a treatment for epilepsy

You may not qualify if:

  • Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Drexel University Nutrition Sciences Research Lab

Philadelphia, Pennsylvania, 19102, United States

Location

Drexel University

Philadelphia, Pennsylvania, 19102, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Serum and urine samples

MeSH Terms

Conditions

EpilepsyMagnesium DeficiencyVitamin D Deficiency

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic DiseasesAvitaminosis

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 14, 2018

First Posted

March 20, 2018

Study Start

August 10, 2015

Primary Completion

August 1, 2019

Study Completion

August 1, 2019

Last Updated

March 1, 2021

Record last verified: 2019-11

Locations